Diagnostic and progression biomarkers in cerebrospinal fluid of Alzheimer’s disease patients
Miyo K. Chatanaka, Ioannis Prassas, Eleftherios P. Diamandis
TL;DR
This commentary evaluates the reliability of a new method for finding Alzheimer’s disease biomarkers in cerebrospinal fluid and discusses challenges in applying these findings to patient care.
Contribution
The paper critically assesses the translational potential and robustness of newly discovered Alzheimer’s biomarkers in cerebrospinal fluid.
Findings
The commentary reviews the method's reliability for identifying diagnostic biomarkers in Alzheimer’s disease.
It highlights translational challenges in applying these biomarkers to assist Alzheimer’s patients and those at risk.
Abstract
In this commentary, we address a paper published by Johnson et al. by assessing the robustness of their method to discover diagnostic biomarkers in Alzheimer’s disease (AD). In addition, we examine how these newly discovered and previously discovered biomarkers, can play a role in assisting patients with AD and those at risk for developing AD, with an emphasis on the translational hurdles that accompany such discoveries.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsAlzheimer's disease research and treatments · Dementia and Cognitive Impairment Research · S100 Proteins and Annexins